{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:51:16Z","timestamp":1790941876281,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS097876"],"award-info":[{"award-number":["NS097876"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS080168"],"award-info":[{"award-number":["NS080168"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RX003798"],"award-info":[{"award-number":["RX003798"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017016","name":"Geriatric Research Education and Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RX003798"],"award-info":[{"award-number":["RX003798"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CX001621"],"award-info":[{"award-number":["CX001621"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RX000995"],"award-info":[{"award-number":["RX000995"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["C1920407"],"award-info":[{"award-number":["C1920407"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG028747"],"award-info":[{"award-number":["AG028747"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG000513"],"award-info":[{"award-number":["AG000513"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jvs.2025.10.101","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:12:58Z","timestamp":1765782778000},"page":"1249-1258.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A systematic review and meta-analysis of the impact of clopidogrel responsiveness on ischemic and bleeding complications after noncoronary endovascular procedures"],"prefix":"10.1016","volume":"83","author":[{"given":"Ashling L.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Crone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Jreij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-7367","authenticated-orcid":false,"given":"Aidan P.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbey N.","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2131-1751","authenticated-orcid":false,"given":"Joy Y.","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarasijhaa K.","family":"Desikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Sorkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-8201","authenticated-orcid":false,"given":"Brajesh K.","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2025.10.101_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008791","article-title":"Discharge prescription patterns for antiplatelet therapy following lower extremity peripheral vascular intervention","volume":"13","author":"Singh","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2025.10.101_bib2","first-page":"1580","article-title":"Dual antiplatelet therapy: a concise review for clinicians","volume":"13","author":"Virk","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jvs.2025.10.101_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2025.10.101_bib4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1253\/circj.CJ-21-0751","article-title":"Antiplatelet therapy after percutaneous coronary intervention \u2014 past, current and future perspectives","volume":"86","author":"Natsuaki","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jvs.2025.10.101_bib5","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2025.01.018","article-title":"2025 acute coronary syndromes guideline-at-a-glance","volume":"85","author":"Dharam","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib6","first-page":"E18","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.123.067767","article-title":"Antiplatelet therapy after PCI: the art and science of de-escalation","volume":"149","author":"Storey","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib8","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1161\/01.CIR.0000035924.70846.20","article-title":"Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective","volume":"106","author":"Berger","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib9","first-page":"e726","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib10","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.jacc.2024.04.003","article-title":"2024 lower extremity peripheral artery disease guideline-at-a-Glance","volume":"83","author":"Bates","year":"2024","journal-title":"J Am coll cardiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib11","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib12","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib13","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor\u2019s choice - European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2025.10.101_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejvs.2024.05.034","article-title":"Patient factors influencing prescription of antithrombotic medication after lower limb endovascular intervention","volume":"68","author":"Zhu","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2025.10.101_bib15","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.jvsvi.2024.100153","article-title":"Antithrombotic therapy following lower extremity endovascular revascularization: the results of a survey of vascular specialists","volume":"2","author":"Jarosinski","year":"2024","journal-title":"JVS Vasc Insights"},{"key":"10.1016\/j.jvs.2025.10.101_bib16","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jvs.2025.10.101_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/jpm8010008","article-title":"Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine","volume":"8","author":"Brown","year":"2018","journal-title":"J Pers Med"},{"key":"10.1016\/j.jvs.2025.10.101_bib18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2025.10.101_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jvs.2025.10.101_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCINTERVENTIONS.111.962183","article-title":"Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting","volume":"4","author":"Sibbing","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jvs.2025.10.101_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jvs.2025.10.101_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jvs.2014.01.068","article-title":"Antiplatelet effects of clopidogrel dose adjustment (75 mg\/d vs 150 mg\/d) after carotid stenting","volume":"60","author":"Gonz\u00e1lez","year":"2014","journal-title":"J Vasc Surg"},{"issue":"SUPPL.1","key":"10.1016\/j.jvs.2025.10.101_bib23","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.2459\/JCM.0b013e328364bd25","article-title":"Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests","volume":"14","author":"Valgimigli","year":"2013","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.jvs.2025.10.101_bib24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jvs.2025.10.101_bib25","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1160\/TH11-03-0202","article-title":"Prevalence of poor biological response to clopidogrel: a systematic review","volume":"107","author":"Mallouk","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvs.2025.10.101_bib26","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jvs.2025.10.101_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jvs.2025.10.101_bib28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5551\/jat.64326","article-title":"Utility of the ACD-GENE-CLI score in Asian patients with critical limb ischemia undergoing endovascular interventions","volume":"31","author":"Chang","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jvs.2025.10.101_bib29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jvs.2014.03.293","article-title":"Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease","volume":"60","author":"Guo","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvs.2025.10.101_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejvs.2019.02.011","article-title":"CYP2C19 polymorphism is associated with amputation rates in patients taking clopidogrel after endovascular intervention for critical limb ischaemia","volume":"58","author":"Lee","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2025.10.101_bib31","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3174\/ajnr.A4481","article-title":"Association between CYP2C19 polymorphisms and outcomes in cerebral endovascular therapy","volume":"37","author":"Lin","year":"2016","journal-title":"ANJR Am J Neuroradiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib32","first-page":"6065","article-title":"The correlation between platelet responsiveness to clopidogrel and CYP2C19 polymorphism in patients with peripheral vascular disease","volume":"25","author":"El-Khodary","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jvs.2025.10.101_bib33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/2022.12.JNS222316","article-title":"Natural history of antiplatelet nonresponders undergoing carotid artery stenting","volume":"139","author":"Muram","year":"2023","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jvs.2025.10.101_bib34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/17085381221142219","article-title":"Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization","volume":"32","author":"Rokosh","year":"2024","journal-title":"Vascular"},{"key":"10.1016\/j.jvs.2025.10.101_bib35","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.04.014","article-title":"The roles and issues of P2Y12 percent inhibition assessed by verifynow assay for patients undergoing neurointervention: a prospective study","volume":"23","author":"Kashiwazaki","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jvs.2025.10.101_bib36","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3174\/ajnr.A3418","article-title":"Clopidogrel hyper-response and bleeding risk in neurointerventional procedures","volume":"34","author":"Goh","year":"2013","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib37","author":"Dean"},{"key":"10.1016\/j.jvs.2025.10.101_bib38","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2025.10.101_bib39","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2025.10.101_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jvs.2025.10.101_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jvs.2025.10.101_bib42","first-page":"90","article-title":"Platelet function testing-guided antiplatelet therapy","volume":"24","author":"Lenk","year":"2013","journal-title":"EJIFCC"},{"key":"10.1016\/j.jvs.2025.10.101_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y12 inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib44","doi-asserted-by":"crossref","first-page":"19630","DOI":"10.1161\/JAHA.120.019630","article-title":"Factors related to major bleeding after ticagrelor therapy: results from the tico trial","volume":"10","author":"Cho","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jvs.2025.10.101_bib45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"180","author":"Turgeon","year":"2020","journal-title":"JAMA Intern med"},{"key":"10.1016\/j.jvs.2025.10.101_bib46","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","article-title":"Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?","volume":"125","author":"Gurbel","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2025.10.101_bib47","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jacc.2024.02.015","article-title":"Effectiveness of clopidogrel vs alternative P2Y12 inhibitors based on the ABCD-GENE score","volume":"83","author":"Thomas","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jon.12714","article-title":"The effect of ticagrelor on platelet reactivity in patients with clopidogrel resistance undergoing neuroendovascular procedures","volume":"30","author":"Qureshi","year":"2020","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.jvs.2025.10.101_bib49","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s00270-014-0852-y","article-title":"Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures","volume":"37","author":"Spiliopoulos","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvs.2025.10.101_bib50","first-page":"207","article-title":"Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy","volume":"80","author":"Tajima","year":"2018","journal-title":"Nagoya J Med Sci"},{"key":"10.1016\/j.jvs.2025.10.101_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1179\/1743132815Y.0000000084","article-title":"Accumetrics-based clopidogrel dosing in endovascular neurosurgery","volume":"37","author":"Wong","year":"2015","journal-title":"Neurol Res"},{"key":"10.1016\/j.jvs.2025.10.101_bib52","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jvs.2025.10.101_bib53","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1111\/bcp.14637","article-title":"Genotype-guided antiplatelet treatment versus conventional therapy: a systematic review and meta-analysis","volume":"87","author":"Zhang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jvs.2025.10.101_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41397-020-00189-2","article-title":"The need of a multicomponent guiding approach to personalize clopidogrel treatment","volume":"21","author":"Valeria","year":"2021","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jvs.2025.10.101_bib55","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/eurheartj\/ehac046","article-title":"Time for a paradigm shift? Making the case for tailored selection of antiplatelet therapy","volume":"43","author":"O\u2019donoghue","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2025.10.101_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.avsg.2022.12.071","article-title":"A systematic review of clopidogrel resistance in vascular surgery: current perspectives and future directions","volume":"91","author":"Kim","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvs.2025.10.101_bib57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-3565(24)34944-4","article-title":"A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin","volume":"290","author":"Ibeanu","year":"1999","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521425021573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521425021573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:08:21Z","timestamp":1781496501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521425021573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0741521425021573"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2025.10.101","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of the impact of clopidogrel responsiveness on ischemic and bleeding complications after noncoronary endovascular procedures","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2025.10.101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2025.12.152","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 THE AUTHOR(S). Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.","name":"copyright","label":"Copyright"}]}}